IB Net Payout Yields Model

Novavax: The Gig Is Up


  • Novavax has issued dire warnings to shareholders as the company continues to burn substantial amounts of cash.
  • The small biotech continues to dilute shareholders via near-endless share issuances, and no guarantees exist that the company will have a successful 2023 vaccine update.
  • Novavax stock is one to avoid, even after crashing below $7 on the dire warning.
Anyone historically following Novavax, Inc. (NASDAQ:NVAX) could've predicted this ending for the biotech focusing on vaccines. The company has a history of promising new vaccines while constantly diluting shareholders over and over with new share issuance. The stock

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 


Popular posts from this blog

Kohl's: Worth $75 Without Financial Engineering

Stat of the Day: Leading Indicators Jump Again

Out Fox The $treet - December 13, 2019